在早期乳腺癌中使用abemaciclib的整体存活率
S Johnston1, M Martin2, J O'Shaughnessy3
1The Royal Marsden NHS Foundation Trust, London, UK.
概括
辅助性abemaciclib与内分泌疗法 (ET) 显著改善了整体存活率 (OS),并降低了高风险早期乳腺癌 (EBC) 患者的死亡风险. 这种组合疗法还在侵袭性无疾病存活率 (IDFS) 和远程无复发存活率 (DRFS) 中表现出持续的益处.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 辅助性abemaciclib与内分泌疗法 (ET) 结合,对高风险早期乳腺癌 (EBC) 的侵袭性无病生存率 (IDFS) 显著改善.
- 这种组合对整体存活时间 (OS) 的影响以前是未知的.
研究的目的:
- 报告来自III期monarchE试验的初级总生存 (OS) 结果.
- 提供无侵袭性疾病生存率 (IDFS) 和远程无复发生存率 (DRFS) 的最新估计.
主要方法:
- 在monarchE试验中,随机选择了5637名HR阳性,HER2阴性,结节阳性,高风险EBC患者.
- 患者接受了至少5年的ET,有或没有2年的abemaciclib.
主要成果:
- 随访时间中位数为76.2个月,abemaciclib-ET使死亡风险降低了15.8% (HR 0.842,P=0.027),达到统计学意义.
- 七年后的生存率为abemaciclib-ET的86.8%,与ET的85.0%相比. 观察到IDFS和DRFS的持续改善,7年IDFS为77.4%和7年DRFS为80.0%的abemaciclib-ET.
- 长期安全数据没有显示延迟毒性.
结论:
- 辅助剂abemaciclib-ET为高风险EBC患者提供了统计学上显著和临床上有意义的OS改善.
- 组合疗法在7年内显示出持续的IDFS和DRFS益处,加强了其在管理高风险早期乳腺癌中的作用.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
810
相关概念视频
Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
